WO2009031922A1 - Tablet for prophylaxis and treatment of dental and periodontium diseases - Google Patents
Tablet for prophylaxis and treatment of dental and periodontium diseases Download PDFInfo
- Publication number
- WO2009031922A1 WO2009031922A1 PCT/RU2008/000424 RU2008000424W WO2009031922A1 WO 2009031922 A1 WO2009031922 A1 WO 2009031922A1 RU 2008000424 W RU2008000424 W RU 2008000424W WO 2009031922 A1 WO2009031922 A1 WO 2009031922A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium
- tablet
- prophylaxis
- dental
- teeth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
Definitions
- the invention relates to medicine or rather to stomatology, in particular to tablet for prophylaxis and treatment of dental and periodontium diseases.
- Prophylactic effect of this medication is grounded on a well-known fluor action, focused on enamel and osseous tissue strengthening. Fluor is more effective with associated sufficient content of calcium and vitamins whereas it does not provide their ingress since calcium phosphate digests badly.
- the known medication does not secure integrated effect aimed at treatment and prophylaxis of dental and periodontium diseases.
- This drug is administered to patients suffering from constant formation of dental calculi. Treatment course takes a month. There are administered 2-4 tablets a day. The drug ensures bacterial and calculi elimination and for this reason it serves as a means of prophylaxis of stomatological diseases, caries in particular.
- the known medication does not involve components aimed at prophylaxis of a number of oral diseases. Notwithstanding Ascophyllum nodosum is one of the most widespread seaweeds it is not present in traditional human diet.
- Substance of invention The major focus of the present invention is on elaboration of complex formulation in the form of tablet of easy-digestible mineral components, vitamins, microelements intended to make them act as synergists ensuring either local or systemic effect by ingress of required substances in optimal quantities for the sake of treatment and prophylaxis of oral diseases and foremost caries and non-carious teeth affections.
- Tablet for prophylaxis and treatment of teeth and periodontium diseases involves following components at a ratio (wt %):
- Therapeutic and prophylactic effect of the drug for treatment and prophylaxis of oral diseases is entailed by a combined influence of pyridoxine hydrochloride, thiamin mononitrate, calcium glycerophosphate, laminaria thallus, booster dose of magnesium sulfate, sorbite and xylitol.
- the drug ensures increase of body functional reserves, enforcing physiological process of teeth tissues mineralization.
- Calcium glycerophosphate penetrates easily into mineralized tissues and foremost into teeth and bones that is why in given formulation it is a source of calcium and phosphor for teeth and tissues of periodontium therefore enforcing mineralization processes and increasing anti-carious effect of formulation as a whole.
- calcium glycerophosphate is a regulator of calcium and phosphor metabolism, endowed with bracing and roborant effect by heightening metabolic processes in human body.
- Pyridoxine hydrochloride (vitamin B 6 ) is an active participator in metabolism relevant for normal functioning of central and peripheral nervous system. Penetrating into body it phosphorilates, transforms into pyridoxole-5- phosphate and forms enzymes which decarboxilate and transaminate aminoacids, i.e. it plays active part in most important life processes. It takes part in metabolism of essential aminoacids, such as methionine tryptophane, cystein, glutamic and other aminoacids. It plays important role in histamine metabolism, contributes to normalization of lipidic and according to some data, carbohydrate metabolism, heightening prophylactic effect of formulation as a whole. Vitamin B 6 participates directly in maintaining of structure and bone solidity.
- vitamin B 1 Thiamin mononitrate (vitamin B 1 ) on penetrating into body transforms into co- fermentative forms of fermentative systems which play relevant part in carbohydrate and fats metabolism and in nerve impulse conduction in synapse as well. All processes of intestinal absorption carried out by mechanism of active energy-depended transport; increase and renewal of intestinal enterocytes and osseous cells; synthesis of collagen and other proteins of osseous tissue require constant flow of energy which is drawn from processes of biological oxidation. Vitamin B 1 is indispensable participator in such processes.
- Ground laminaria thallus (seaweed) or dried laminaria aqueous extract contain complex of most important microelements (titanium, nickel, cuprum, argentum, iodine, zinc, ferrum etc.), macroelements (phosphor, calcium, magnesium etc.), aminoacids including all essential ones like chlorophyll, carotinoids, vitamins; polysaccharides like alginic acid, fucoidane, laminarm. If the components indicated presented in one product they perform the function of active synergists. In confirmation to scientific research there are no collateral phenomena observed in seaweed use which is traditional human food product.
- laminaria The basic advantage of laminaria is iodine content which digests better and improves protein, phosphor, calcium, ferrum assimilation, activates fermentative systems as well. Moreover laminaria eliminates vitamin-mineral deficiency and brings to normal nervous, cardio-vascular and respiratory systems and builds up immune system, fosters normalization of thyroid function. In whole it ensures physiological body homeostasis.
- Magnesium salt, magnesium sulfate, magnesium chloride listed among inorganic magnesium salts or magnesium lactate, magnesium oxalate from the list of organic magnesium salts is added into formulation as magnesium source relevant for regulation of many physiological metabolism processes including intra- and extracellular balance of potassium, magnesium, sodium and calcium in a body on cellular level that improves prophylactic effect of formulation as a whole.
- magnesium forms mineral base of osseous tissue. It plays important part in osteogenesis and can influence directly osseous cells function, vitamin D and calcium metabolism, formation and growth of oxyapatite crystals.
- Stevioside stevia herb extract
- active antioxidants in this extract such as flavonoids, hydroxyl-proline acids, cumarins
- potassium, magnesium, zinc, selenium, ferrum, calcium and sodium that as a whole enhance prophylactic effect of formulation.
- Xylite, sorbite have bacteriostatic effect inhibiting growth of dentogingival plaque and streprococci metabolism, contributes to pH saliva level thereby securing favourable environment for enamel mineralization especially combined with complex of mineral and other bioactive substances. It is matter of high priority since formulation is intended for systemic and local (dental) effect.
- realization tablet involves following auxiliary components at a ratio, wt %:
- Lactose, cocoa-powder, food flavors, banding and lubricating auxiliary components ensure process of formulation pelletizing and its pleasing flavor.
- Calcium phosphate serves as a filler.
- As a banding component necessary for tablet formation it is preferable to use soya or milk protein or fructose.
- As a lubricating component relevant for flowability improvement and adhesiveness reduction in tablets pressing it is preferable to use magnesium stearate however there may be used calcium stearate or stearic acid.
- Proposed formulation in the form of lozenge is devised for systemic and local (on teeth directly) prophylactic action that is why some components perform two functions; of locally-acting agent and filler.
- some components there are listed sorbite, xylite, stevioside. Realization of invention
- table 1 there are listed average readings of active components content in tablets with mass of 1000 mg. according to their optimal ingress into body.
- auxiliary components like sorbite, xylite, soya protein, stevioside, cocoa-powder, magnesium stearate, calcium phosphate.
- formulation in the form of lozenge is similar to example 1 but components are represented at optimal (medial) ratio.
- Lozenge preparation is carried out according to usual tablet technique.
- Tablets are applied in order to improve dental tissues mineralization and for prophylaxis and treatm A tt caon a pp e r ent of dental hypersensitivity. It is illustrative that tablets invented are efficient in its elimination.
- Figures represented in table 3 show a sharp change in indices of hygiene, prevalence and intensity that testifies to enhancing of teeth remineralization. The difference is significant (p ⁇ 0.05).
- Example 1 Patient X, 39 years of age, complained on high teeth sensitivity, sore and gingival hemorrhage, offensive breath. Up to this complaint she had used only fluor- containing tooth-pastes for regular hygiene.
- objective results of the investigation :
- Hygiene index 2.75 points; Schiller-Pisarev test - positive;
- example 2 in table 2 proposed formulation in the form of lozenge with optimal component content (example 2 in table 2) is intended for systemic and local effect on periodontium tissues due to physiological process of enamel and dentin remineralization. Besides there was administered other tooth-paste because dental deposit elimination aids to enhance local effect of formulation.
- Hygiene index 1.65 points; Schiller-Pisarev test - weak positive;
- Hygiene index dropped to 1.6 points
- Hygiene index improved to 1.5 points
- Example 3 Patient Z, 39 years of age, complained on expressed hypersensitivity of almost all teeth after meals, cold drinks and sweets. Besides there were marked hemorrhage and gingivitis.
- tooth paste On teeth scaling and standard teeth and periodontium tissues antiseptic treatment (with 3% solution of hydrogen peroxide and rose solution of potassium permanganate) there was tooth paste recommended and administered invented tablets (their formulation is illustrated in example 2, table 2).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to stomatology and specifically to tablet for prophylaxis and treatment of dental and periodontium diseases. The tablet contains following components at a ratio, wt %: Magnesium sulfate or magnesium chloride or magnesium lactate or magnesium oxalate: 3.26-5.26, Pyridoxine hydrochloride: 0.060-0.074, Thiamin mononitrate: 0.50-0.062, Calcium glycerophosphate: 30.0-38.9, Ground laminaria thallus or dried laminaria aqueous extract: 1.1-2.2, Stevioside: 0.3-0.9, Sorbite: 10.0-25.0, Xylite: 10.0-25.0, Auxiliary components: 15.62-45.42
Description
Tablet for prophylaxis and treatment of dental and periodontium diseases
Field of application The invention relates to medicine or rather to stomatology, in particular to tablet for prophylaxis and treatment of dental and periodontium diseases.
Background of invention
Prophylaxis of oral diseases including dental caries has been a matter of long and continuous interest of scientists and experts. Fluor is known for its prophylactic and anti-carious effect. It reduces caries morbidity by 30-45% entering with drinking water, fluorated milk and salt. Herewith it is more effective along with sufficient calcium content in drinking water. (Yu.A. Fedorov Prophylaxis of dental and oral cavity diseases. L.:Meditsina, 1979, pp32-35). Hopeful results were obtained while using vitamins Bi and B6. ( Yu.A. Fedorov
Clinical course and treatment of hypersensitivity of hard tooth tissues, L.:Meditsina, 1970, pp 94-95). Rather contradictory data about prophylactic action of microelements were specified in the following research papers: Yu.A. Fedorov Prophylaxis of dental and oral cavity diseases. L.:Meditsina, 1979, pp34-38; N.A. Kodola Microelements in prophylaxis of teeth caries, Kiev, Zdorovie, 1979, pp 110,117,122. Alongside there were represented investigation results pointing to constant mineral renewal of teeth tissues through ingress of micro- and macroelements from saliva, drink and food. This physiological process renders it possible to prevent and even treat dental diseases like for example, hypersensitivity. (Yu.A. Fedorov Clinical course and treatment of hypersensitivity of hard tooth tissues, L.:Meditsina, 1970, ppl05-107).
There is known formulation in the form of tablets of sodium fluoride thoroughly used in stomatology. Among disadvantages of this medication there are listed the following:
- it is difficult to control total fluor ingress from various sources; - it does not have integrated effect since it lacks anti-inflammatory function;
- there are use limitations for elder patients.
According to a number of authors fluoride can reduce bone strength especially in a state with high metabolism speed. (Riggs B.L., Melton III L.G. Osteoporosis - tr. from Eng. M-Spb: ZAO Izdatelstvo Binom, Nevski Dialekt, 2000, p441).
It is known that combined application of endogeneous calcium medications and local formulation makes it possible to increase treatment efficacy. (Yu. A. Fedorov, V.A. Drozhzhina Clinical course, diagnostics and treatment of noncarious lesions of teeth. Novoe v stomatologic, XsIO (60), 1997, Special Issue, pp 43-44, 80-81).
There is known medication used in various forms, in the form of tablet inclusively. It contains surface-active components: sulfanate olefins, components of abrasive action like sodium methaphosphate or calcium phosphate while fluorides may be added into formulation as well. (GB NoI 172904 IPC A61K7/16, 1969).
Prophylactic effect of this medication is grounded on a well-known fluor action, focused on enamel and osseous tissue strengthening. Fluor is more effective with associated sufficient content of calcium and vitamins whereas it does not provide their ingress since calcium phosphate digests badly. The known medication does not secure integrated effect aimed at treatment and prophylaxis of dental and periodontium diseases.
There is known tablet for oral application intended for dental deposit reduction, containing dry powder of seaweed Ascophyllum nodosum (RU C2 No2275218, IPC 8 A61Q 11/00, 2006).
This drug is administered to patients suffering from constant formation of dental calculi. Treatment course takes a month. There are administered 2-4 tablets a day. The drug ensures bacterial and calculi elimination and for this reason it serves as a means of prophylaxis of stomatological diseases, caries in particular. However the known medication does not involve components aimed at prophylaxis of a number of oral diseases. Notwithstanding Ascophyllum nodosum is one of the most widespread seaweeds it is not present in traditional human diet.
Substance of invention The major focus of the present invention is on elaboration of complex formulation in the form of tablet of easy-digestible mineral components, vitamins, microelements intended to make them act as synergists ensuring either local or systemic
effect by ingress of required substances in optimal quantities for the sake of treatment and prophylaxis of oral diseases and foremost caries and non-carious teeth affections.
The given task is being accomplished in the following way. Tablet for prophylaxis and treatment of teeth and periodontium diseases involves following components at a ratio (wt %):
Magnesium sulfate or magnesium chloride or magnesium lactate or magnesium oxalate 3.26-5.26
Pyridoxine hydrochloride 0.060-0.074
Thiamin mononitrate 0.50-0.062 Calcium glycerophosphate 30.0-38.9
Ground laminaria thallus or dried laminaria aqueous extract 1.1 -2.2
Stevioside 0.3-0.9
Sorbite 10.0-25.0 Xylite 10.0-25.0
Auxiliary components 15.62-45.42
Therapeutic and prophylactic effect of the drug for treatment and prophylaxis of oral diseases is entailed by a combined influence of pyridoxine hydrochloride, thiamin mononitrate, calcium glycerophosphate, laminaria thallus, booster dose of magnesium sulfate, sorbite and xylitol. The drug ensures increase of body functional reserves, enforcing physiological process of teeth tissues mineralization.
Calcium glycerophosphate penetrates easily into mineralized tissues and foremost into teeth and bones that is why in given formulation it is a source of calcium and phosphor for teeth and tissues of periodontium therefore enforcing mineralization processes and increasing anti-carious effect of formulation as a whole. Besides calcium glycerophosphate is a regulator of calcium and phosphor metabolism, endowed with bracing and roborant effect by heightening metabolic processes in human body.
Pyridoxine hydrochloride (vitamin B6) is an active participator in metabolism relevant for normal functioning of central and peripheral nervous system. Penetrating into body it phosphorilates, transforms into pyridoxole-5- phosphate and forms enzymes which decarboxilate and transaminate aminoacids, i.e. it plays active part in most important life processes. It takes part in metabolism of essential aminoacids, such as
methionine tryptophane, cystein, glutamic and other aminoacids. It plays important role in histamine metabolism, contributes to normalization of lipidic and according to some data, carbohydrate metabolism, heightening prophylactic effect of formulation as a whole. Vitamin B6 participates directly in maintaining of structure and bone solidity. Thiamin mononitrate (vitamin B1) on penetrating into body transforms into co- fermentative forms of fermentative systems which play relevant part in carbohydrate and fats metabolism and in nerve impulse conduction in synapse as well. All processes of intestinal absorption carried out by mechanism of active energy-depended transport; increase and renewal of intestinal enterocytes and osseous cells; synthesis of collagen and other proteins of osseous tissue require constant flow of energy which is drawn from processes of biological oxidation. Vitamin B1 is indispensable participator in such processes.
Ground laminaria thallus (seaweed) or dried laminaria aqueous extract contain complex of most important microelements (titanium, nickel, cuprum, argentum, iodine, zinc, ferrum etc.), macroelements (phosphor, calcium, magnesium etc.), aminoacids including all essential ones like chlorophyll, carotinoids, vitamins; polysaccharides like alginic acid, fucoidane, laminarm. If the components indicated presented in one product they perform the function of active synergists. In confirmation to scientific research there are no collateral phenomena observed in seaweed use which is traditional human food product. The basic advantage of laminaria is iodine content which digests better and improves protein, phosphor, calcium, ferrum assimilation, activates fermentative systems as well. Moreover laminaria eliminates vitamin-mineral deficiency and brings to normal nervous, cardio-vascular and respiratory systems and builds up immune system, fosters normalization of thyroid function. In whole it ensures physiological body homeostasis.
Magnesium salt, magnesium sulfate, magnesium chloride listed among inorganic magnesium salts or magnesium lactate, magnesium oxalate from the list of organic magnesium salts is added into formulation as magnesium source relevant for regulation of many physiological metabolism processes including intra- and extracellular balance of potassium, magnesium, sodium and calcium in a body on cellular level that improves prophylactic effect of formulation as a whole. As well as calcium, magnesium forms mineral base of osseous tissue. It plays important part in
osteogenesis and can influence directly osseous cells function, vitamin D and calcium metabolism, formation and growth of oxyapatite crystals.
Stevioside (stevia herb extract) is applied due to content of active antioxidants in this extract (such as flavonoids, hydroxyl-proline acids, cumarins) and also some potassium, magnesium, zinc, selenium, ferrum, calcium and sodium that as a whole enhance prophylactic effect of formulation.
Xylite, sorbite have bacteriostatic effect inhibiting growth of dentogingival plaque and streprococci metabolism, contributes to pH saliva level thereby securing favourable environment for enamel mineralization especially combined with complex of mineral and other bioactive substances. It is matter of high priority since formulation is intended for systemic and local (dental) effect.
In the preferred option of invention realization tablet involves following auxiliary components at a ratio, wt %:
Lactose 0.12-0.37 Cocoa-powder 0.15-0.35
Calcium phosphate 2.0-5.0
Food flavors 0.3-0.9
Food dye 0.05-0.30
Banding component 12.0-35.0 Lubricating component 1.0-3.5
Lactose, cocoa-powder, food flavors, banding and lubricating auxiliary components ensure process of formulation pelletizing and its pleasing flavor. Calcium phosphate serves as a filler. As a banding component necessary for tablet formation it is preferable to use soya or milk protein or fructose. As a lubricating component relevant for flowability improvement and adhesiveness reduction in tablets pressing, it is preferable to use magnesium stearate however there may be used calcium stearate or stearic acid.
Proposed formulation in the form of lozenge is devised for systemic and local (on teeth directly) prophylactic action that is why some components perform two functions; of locally-acting agent and filler. Among such components there are listed sorbite, xylite, stevioside.
Realization of invention
In table 1 there are listed average readings of active components content in tablets with mass of 1000 mg. according to their optimal ingress into body.
Table 1
*} as a filler there are used auxiliary components like sorbite, xylite, soya protein, stevioside, cocoa-powder, magnesium stearate, calcium phosphate.
^ " ACL - adequate consumption level; recommended levels of consumption of food and bioactive substances. In table 2 there are illustrated specific examples of tablet formulations prepared in compliance with the invention. Use of other magnesium salts listed among those corresponding to the invention, particularly magnesium chloride or magnesium lactate or magnesium oxalate instead of magnesium sulfate indicated in the examples, yields to similar results and does not tell on effectiveness of medication.
In accordance with method of formulation preparation in the form of lozenge, in example 1 there is demonstrated maximal dosage of components.
In example 2, formulation in the form of lozenge is similar to example 1 but components are represented at optimal (medial) ratio.
In example 3 there are represented data of formulation in the form of lozenge with minimal content of components.
Lozenge preparation is carried out according to usual tablet technique.
First there is obtained mass for pelletizing by porphyrizing, dosing, sorting, mixing of components, then it is subjected to wet granulation, powdering and mixing.
Table 2
Later the prepared mass is pelletized, tablets are dedusted and packed.
Mustered-out tablets are directed to recycling.
Described technique does not undergo any changes if there were used other components corresponding to the invention but not indicated in table 2; neither does it in case of application of various auxiliary components corresponding to the invention.
Tablets should be resolved, therefore a part of active components is actively
Btcao appeoren absorbed through mucous membrane and other part while in a mouth will have local reminera gefi Atlt tcaoernizing influence.
It is prescribed to use 2-3 tablets during the day after teeth brushing. This course takes 1-1.5 mont Bthcaon appeore. Second course will take place in 5-6 months.
Tablets are applied in order to improve dental tissues mineralization and for prophylaxis and treatm Attcaon apperent of dental hypersensitivity. It is illustrative that tablets invented are efficient in its elimination.
Btcaon appeore
22 volunteers agreed to participate in the studies. There were studied and analyzed processes of enamel reminera Att naon apperlization on the ground of determination of index of teeth hypersensitivity prevalence (ITHP), intensity (ITHI), hygiene index, PMA and Schiller-Pisarev test. Btcaon appeore
In table 3 there are shown hygiene index and dental hypersensitivity readings obtained during the survey. Atton ca apper
Table 3
Figures represented in table 3 show a sharp change in indices of hygiene, prevalence and intensity that testifies to enhancing of teeth remineralization. The difference is significant (p < 0.05).
Alongside substantial improvement of periodontium state has been observed according to all objective indices (index ±PMA and Schiller-Pisarev test). The difference is significant (p < 0.01).
Hereafter there are shown examples of application of tablets for prophylaxis and treatment of dental and periodontium diseases in medical practice.
Example 1 Patient X, 39 years of age, complained on high teeth sensitivity, sore and gingival hemorrhage, offensive breath. Up to this complaint she had used only fluor- containing tooth-pastes for regular hygiene. Here are objective results of the investigation:
Hygiene index — 2.75 points; Schiller-Pisarev test - positive;
PMA index - 38.6%;
ITHP - 49.8%
ITHI - 2.35 points.
On teeth scaling periodontium tissues and teeth were treated according to traditional method, rinsed by solution of hydrogen peroxide and potassium permanganate.
Then there were given teeth care instructions to the patient since proposed formulation in the form of lozenge with optimal component content (example 2 in table 2) is intended for systemic and local effect on periodontium tissues due to physiological process of enamel and dentin remineralization. Besides there was administered other tooth-paste because dental deposit elimination aids to enhance local effect of formulation.
On 32 days of new formulation application the patient had no complaints. There was marked next to complete disappearance of gingival hemorrhage and gingivitis and offensive breath as well. Teeth hypersensitivity reduced considerably.
Here are objective results of the investigation:
Hygiene index - 1.65 points;
Schiller-Pisarev test - weak positive;
PMA index - 12.3%;
ITHP - 23.7%;
ITHI - 1.58 points. On 62 days of the survey therapeutic effect of medication became more pronounced. There were no complaints.
Hygiene index - 1.45 points;
Schiller-Pisarev test -negative;
PMA index dropped to 8.5%; ITHP - 17.6%;
ITHI - 1.2 points.
Teeth hypersensitivity practically disappeared.
Example 2
Patient Y5 28 years of age, complained on oversensitivity of almost all teeth, frequent gingival hemorrhage and edema, itch in oral cavity tissues.
According to objective results:
Hygiene index — 3.2 points;
Schiller-Pisarev test -positive;
PMA index - 38.7%; ITHP - 65.6 %;
ITHI - 2.35 points.
On scaling teeth and periodontium underwent antiseptic preparation. There was tooth-paste recommended and administered medication for three-time application prepared in accordance with the invention at a minimal content of active components (example 3 table 2).
On 33 days of tablets application the patient felt notable improvement; recorded gingival hemorrhage and gingivitis reduction.
Hygiene index dropped to 1.6 points;
Schiller-Pisarev test became weak positive; ITHP - 42.5 %;
ITHI - 1.65 points.
Teeth hypersensitivity weakened.
On 65 days of medication application indices of teeth state improvement became more evident.
Hygiene index improved to 1.5 points;
Schiller-Pisarev test - negative. Inflammation qualitative signs were not elicited; PMA index dropped to 17.2%;
ITHP - 14.6 %;
ITHI - 1.4 points.
Dentin hypersensitivity practically disappeared.
Example 3 Patient Z, 39 years of age, complained on expressed hypersensitivity of almost all teeth after meals, cold drinks and sweets. Besides there were marked hemorrhage and gingivitis.
According to objective results:
Hygiene index -3.5 points; Schiller-Pisarev test -positive;
PMA index - 38.6%;
ITHP - 63.6 %;
ITHI - 2.8 points.
On teeth scaling and standard teeth and periodontium tissues antiseptic treatment (with 3% solution of hydrogen peroxide and rose solution of potassium permanganate) there was tooth paste recommended and administered invented tablets (their formulation is illustrated in example 2, table 2).
In 35 days it was recorded substantial reduction of gingival hemorrhage and edema, teeth hypersensitivity to various stimuli (thermal, chemical and to touch). Hygiene index -1.9 points;
Schiller-Pisarev test - weak positive;
PMA index - 18.3 %;
ITHP - 22.8 %;
ITHI - 1.65 points. In 65 days the survey revealed disappearance of gingival hemorrhage and edema and next to complete absence of teeth hypersensitivity.
Hygiene index -1.5 points;
Schiller-Pisarev test -negative;
PMA index - 11.4 %;
ITHP - 13.6%;
ITHI - 1.3 points. Thus the examples illustrated point to positive influence of medication on teeth and mouth cavity tissues while at optimal and medial balance of components results of application of new formulation in the form of chewing tablets have been better.
Use of medication for prophylaxis of dental and periodontium diseases has made it possible to enhance tissues mineralization, eliminate or reduce dentin hypersensitivity according to objective ITHP and ITHI figures; along with gingivitis and gingival hemorrhage according to PMA index and Schiller-Pisarev test dynamics. It was caused by hypersensitivity elimination and teeth-brushing improvement.
The conducted studies render it possible to recommend this formulation for caries prophylaxis. Application course duration depends on caries intensity. If there formed one cavity in a year, one-month course is recommended twice a year. If there formed two or more cavities in a year, two month courses are recommended with four month intervals between them.
Claims
1. Tablet for prophylaxis and treatment of dental and periodontium diseases containing following components at a ratio, wt %: Magnesium sulfate or magnesium chloride or magnesium lactate or magnesium oxalate 3.26-5.26
Pyridoxine hydrochloride 0.060-0.074
Thiamin mononitrate 0.50-0.062
Calcium glycerophosphate 30.0-38.9
Ground laminaria thallus or dried laminaria aqueous extract 1.1-2.2
Stevioside 0.3-0.9
Sorbite 10.0-25.0
Xylite 10.0-25.0
Auxiliary components 15.62-45.42
2. Tablet according to point 1 contains following auxiliary components at a ratio, wt %:
Lactose 0.12-0.37
Cocoa-powder 0.15-0.35
Calcium phosphate 2.0-5.0
Food flavors 0.3-0.9
Food dye 0.05-0.30
Banding component 12.0-35.0
Lubricating component 1.0-3.5
3. Tablet according to point 2 differs in fact that auxiliary component is soya or milk protein or fructose.
4. Tablet according to point 2 differs in fact that lubricating auxiliary component is stearic acid or magnesium stearate or calcium stearate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200701932A EA200701932A1 (en) | 2007-08-29 | 2007-08-29 | TABLET FOR PREVENTION AND TREATMENT OF TEETH DISEASES AND PERIODONTAL |
EA200701932 | 2007-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009031922A1 true WO2009031922A1 (en) | 2009-03-12 |
Family
ID=40429096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2008/000424 WO2009031922A1 (en) | 2007-08-29 | 2008-07-01 | Tablet for prophylaxis and treatment of dental and periodontium diseases |
Country Status (3)
Country | Link |
---|---|
EA (1) | EA200701932A1 (en) |
UA (1) | UA88127C2 (en) |
WO (1) | WO2009031922A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2429558A4 (en) * | 2009-05-15 | 2012-12-05 | Obshchestvo S Ogranichennoj Otvetstvennost Yu Wds | Medicine for dental diseases prophylaxis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2708624C1 (en) * | 2019-04-16 | 2019-12-10 | Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет имени М.К.Аммосова" | Method of treating periodontitis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1644963A1 (en) * | 1989-08-22 | 1991-04-30 | Ленинградский Государственный Институт Усовершенствования Врачей Им.С.М.Кирова | Tooth paste |
CN1209314A (en) * | 1997-08-21 | 1999-03-03 | 哈木拉提·吾甫尔 | Oral-cavity cleaning liquor for preventing and curing disease of oral cavity and preparation method thereof |
RU2233651C2 (en) * | 2000-01-27 | 2004-08-10 | Дзе Проктер Энд Гэмбл Компани | Composition for teeth cleansing |
RU2248787C2 (en) * | 2000-10-25 | 2005-03-27 | Дзе Проктер Энд Гэмбл Компани | Compositions for dental care |
RU2275218C2 (en) * | 2000-10-27 | 2006-04-27 | Сдк Свиденкэа Аб | Algae-containing oral remedy for dental plaque and concretion reducing and method for prophylaxis and/or therapy of dental plaque and concretion |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1657188A1 (en) * | 1989-07-17 | 1991-06-23 | Ленинградский Государственный Институт Усовершенствования Врачей Им.С.М.Кирова | Tooth-paste |
RU2293551C1 (en) * | 2005-05-23 | 2007-02-20 | Ооо "Вдс" | Composition for mouth cavity disease prophylaxis |
-
2007
- 2007-08-29 EA EA200701932A patent/EA200701932A1/en unknown
-
2008
- 2008-07-01 UA UAA200906497A patent/UA88127C2/en unknown
- 2008-07-01 WO PCT/RU2008/000424 patent/WO2009031922A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1644963A1 (en) * | 1989-08-22 | 1991-04-30 | Ленинградский Государственный Институт Усовершенствования Врачей Им.С.М.Кирова | Tooth paste |
CN1209314A (en) * | 1997-08-21 | 1999-03-03 | 哈木拉提·吾甫尔 | Oral-cavity cleaning liquor for preventing and curing disease of oral cavity and preparation method thereof |
RU2233651C2 (en) * | 2000-01-27 | 2004-08-10 | Дзе Проктер Энд Гэмбл Компани | Composition for teeth cleansing |
RU2248787C2 (en) * | 2000-10-25 | 2005-03-27 | Дзе Проктер Энд Гэмбл Компани | Compositions for dental care |
RU2275218C2 (en) * | 2000-10-27 | 2006-04-27 | Сдк Свиденкэа Аб | Algae-containing oral remedy for dental plaque and concretion reducing and method for prophylaxis and/or therapy of dental plaque and concretion |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2429558A4 (en) * | 2009-05-15 | 2012-12-05 | Obshchestvo S Ogranichennoj Otvetstvennost Yu Wds | Medicine for dental diseases prophylaxis |
Also Published As
Publication number | Publication date |
---|---|
EA011286B1 (en) | 2009-02-27 |
UA88127C2 (en) | 2009-09-10 |
EA200701932A1 (en) | 2009-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6881419B2 (en) | Vitamin formulation for enhancing bone strength | |
JP7209425B2 (en) | Toothpaste to deliver allergens to the oral mucosa | |
US20120288454A1 (en) | Dental protection toothpaste composition | |
CN108670889A (en) | A kind of toothpaste and preparation method thereof of anti-treating dental ulcer | |
Tinanoff | Use of fluoride | |
CN106176315B (en) | A kind of mouthwash and preparation method thereof | |
US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
CA2441940A1 (en) | Dental formulation | |
CN105920202A (en) | Coenzyme Q10 gum for protecting teeth, strengthening brain and removing odor | |
JP6256770B2 (en) | Oral care composition, tablets, granular drugs | |
EP3290041B1 (en) | Oral care composition | |
WO2009031922A1 (en) | Tablet for prophylaxis and treatment of dental and periodontium diseases | |
US20200030349A1 (en) | Physiologically active preparation comprising n-acetyl-glucosamine for the treatment of back pain | |
Touger-Decker et al. | Position of the American Dietetic Association: the impact of fluoride on health | |
RU2158125C1 (en) | Composition for preventing and treating diseases of periodontium and oral cavity mucosa | |
CN108403544A (en) | A kind of Pediatric Oral Emergency care composition and preparation method thereof | |
RU2763874C1 (en) | Method for the treatment of inflammatory periodontal diseases in women in the menopausal and postmenopausal periods | |
WO2016174861A1 (en) | Oral care composition | |
Yanase et al. | Caries management by risk assessment care paths for prosthodontic patients: Oral microbial control and management | |
RU2006223C1 (en) | Composition for oral cavity diseases prophylaxis | |
RU2772293C1 (en) | Method for treatment of chronic aphthous stomatitis | |
RU2208433C1 (en) | Composite for mouth cavity disease prophylaxis | |
Bobyreva et al. | Endocrinology in dental practice | |
RU2068688C1 (en) | Curative-prophylactic dental paste | |
RU2195304C1 (en) | Stomatological species of medicinal herbs (versions) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08794044 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15.07.2010) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08794044 Country of ref document: EP Kind code of ref document: A1 |